BR112015031729A2 - sistema de classificação, métodos e kit para classificação, prognóstico e tratamento de câncer de mama - Google Patents

sistema de classificação, métodos e kit para classificação, prognóstico e tratamento de câncer de mama

Info

Publication number
BR112015031729A2
BR112015031729A2 BR112015031729A BR112015031729A BR112015031729A2 BR 112015031729 A2 BR112015031729 A2 BR 112015031729A2 BR 112015031729 A BR112015031729 A BR 112015031729A BR 112015031729 A BR112015031729 A BR 112015031729A BR 112015031729 A2 BR112015031729 A2 BR 112015031729A2
Authority
BR
Brazil
Prior art keywords
breast cancer
prognosis
vdr
invention includes
air
Prior art date
Application number
BR112015031729A
Other languages
English (en)
Inventor
A Ince Tan
Original Assignee
Univ Miami
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Miami filed Critical Univ Miami
Publication of BR112015031729A2 publication Critical patent/BR112015031729A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/743—Steroid hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/723—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Radiology & Medical Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

um novo sistema de classificação para o câncer de mama com base no fenótipo de células mamárias normais e vários níveis de expressão do receptor de estrogênio (er), receptor de androgênio (ar) e receptor de vitamina d (vdr). as várias categorias do sistema de classificação são associadas a diferentes taxas de sobrevida e prognóstico. a invenção inclui um método de classificação de câncer de mama que compreende medição dos níveis de er, ar e vdr no tecido canceroso e classificação do câncer de mama em uma das categorias citadas acima de acordo com os níveis de expressão. a invenção inclui um método de previsão do prognóstico de câncer de mama em um paciente e um método para determinação de um regime de tratamento para o câncer de mama dependendo da categoria na qual o câncer de mama é classificado. a invenção inclui um método de tratamento de câncer de mama de acordo com o perfil de expressão de er, ar e vdr detectado no tecido canceroso. kits para detecção dos mesmos também são fornecidos.
BR112015031729A 2013-06-19 2014-06-19 sistema de classificação, métodos e kit para classificação, prognóstico e tratamento de câncer de mama BR112015031729A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361836863P 2013-06-19 2013-06-19
PCT/US2014/043128 WO2014205184A2 (en) 2013-06-19 2014-06-19 Classification system, methods and kit for classifying. predicting and treating breast cancer

Publications (1)

Publication Number Publication Date
BR112015031729A2 true BR112015031729A2 (pt) 2017-07-25

Family

ID=52105505

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015031729A BR112015031729A2 (pt) 2013-06-19 2014-06-19 sistema de classificação, métodos e kit para classificação, prognóstico e tratamento de câncer de mama

Country Status (8)

Country Link
US (1) US20160146819A1 (pt)
EP (1) EP3011055B1 (pt)
JP (1) JP2016524150A (pt)
KR (1) KR20160041901A (pt)
AU (1) AU2014281464B2 (pt)
BR (1) BR112015031729A2 (pt)
CA (1) CA2916165A1 (pt)
WO (1) WO2014205184A2 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3180000A4 (en) * 2014-08-12 2018-03-07 Gillies Mcindoe Research Institute Cancer diagnosis and therapy
KR101781976B1 (ko) * 2015-04-08 2017-10-23 한국과학기술연구원 나노구조 하이브리드 입자 및 그 제조방법, 그리고 상기 입자를 포함하는 장치
JP2018517462A (ja) 2015-05-05 2018-07-05 エイチ リー モフィット キャンサー センター アンド リサーチ インスティテュート インコーポレイテッド 個人化された放射線療法を得るためのシステム及び方法
WO2017008046A1 (en) * 2015-07-08 2017-01-12 Children's Hospital Medical Center Loss of transcriptional fidelity leads to immunotherapy resistance in cancers
JP6938489B2 (ja) * 2015-10-23 2021-09-22 ノバルティス・エイジーＮｏｖａｒｔｉｓ ＡＧ 視野に存在する選択された細胞のバイオマーカー陽性率の値を導き出す方法
JP6898316B2 (ja) * 2015-10-23 2021-07-07 ノバルティス・エイジーＮｏｖａｒｔｉｓ ＡＧ 拡張版ａｑｕａを支援するコンピュータ処理
RU2022108295A (ru) * 2016-06-22 2022-04-06 Эллипсес Фарма Лтд Способы лечения ar+ рака молочной железы
EP3910070A1 (en) * 2017-04-03 2021-11-17 QIAGEN GmbH Method for analyzing the expression of one or more biomarker rna molecules
CA3059634A1 (en) 2017-04-13 2018-10-18 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
EP3840776A4 (en) * 2018-08-22 2022-09-28 Merck Patent GmbH TREATMENT OF TRIPLE-NEGATIVE BREAST CANCER WITH TARGETED TGF-B INHIBITION
EP3866813A4 (en) 2018-10-17 2022-08-03 Senti Biosciences, Inc. COMBINATORY CANCER IMMUNOTHERAPY
US11419898B2 (en) 2018-10-17 2022-08-23 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
WO2022040334A1 (en) 2020-08-18 2022-02-24 Enviro Metals, LLC Metal refinement

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040002067A1 (en) * 2001-12-21 2004-01-01 Erlander Mark G. Breast cancer progression signatures
US20050100888A1 (en) * 2002-03-02 2005-05-12 Imperial College Innovations Limited Methods based on hormone dependency of primary cancer cells
WO2010125117A2 (en) * 2009-04-29 2010-11-04 Ralph Wirtz A method to assess prognosis and to predict therapeutic success in cancer by determining hormone receptor expression levels
KR20130043104A (ko) 2010-04-06 2013-04-29 카리스 라이프 사이언스 룩셈부르크 홀딩스 질병용 순환 생물학적 지표들
US20150024952A1 (en) 2010-12-28 2015-01-22 Arlet Alarcon Molecular profiling for cancer

Also Published As

Publication number Publication date
AU2014281464A1 (en) 2016-02-11
JP2016524150A (ja) 2016-08-12
US20160146819A1 (en) 2016-05-26
WO2014205184A3 (en) 2015-03-12
EP3011055A4 (en) 2017-02-22
WO2014205184A2 (en) 2014-12-24
EP3011055B1 (en) 2019-08-28
EP3011055A2 (en) 2016-04-27
KR20160041901A (ko) 2016-04-18
AU2014281464B2 (en) 2019-09-26
CA2916165A1 (en) 2014-12-24

Similar Documents

Publication Publication Date Title
BR112015031729A2 (pt) sistema de classificação, métodos e kit para classificação, prognóstico e tratamento de câncer de mama
BR112016018044A2 (pt) teste de diagnóstico molecular para prever resposta às drogas antiangiogênicas e prognóstico de câncer
BR112018009071A8 (pt) método para preparar uma amostra, composição homogenizada, métodos para gerar dados, para tratar uma doença, de identificação de um marcador, para determinar o prognóstico de um câncer, para determinar um perfil fenotípico, para armazenar a composição homogenizada, para preparar uma amostra de tecido e preparar a composição homogenizada
BR112017025254A2 (pt) ?métodos para detecção de pelo menos uma mutação em uma pluralidade de genes relacionados ao câncer, selecionar um indivíduo para tratamento e prever a probabilidade de capacidade de resposta ao tratamento?
AR095363A1 (es) Biomarcadores y métodos para el tratamiento de condiciones relacionadas con pd-1 y pd-l1
GB2531881A (en) Method of isolating circulating tumor cells
BR112014018331A8 (pt) Biomarcadores e terapias combinadas usando vírus oncolítico e imunomodulação
WO2018187496A8 (en) PLASMA PROTEIN PROFILING FOR THE EARLY PROGNOSIS OF LUNG CANCER
WO2018201072A3 (en) Apparatus, systems, and methods for rapid cancer detection
BR112018070683A2 (pt) dispositivo e método para medir distâncias de visualização
BR112016019836A2 (pt) método para analisar uma amostra de um sujeito, dispositivo de diagnóstico para utilização no diagnóstico da endometriose, kit, uso de um biomarcador, e, método para aumentar uma resposta de anticorpos em um sujeito
BR112016029190A2 (pt) método e sistema de detecção de defeitos em tubulações.
BR112018006393A2 (pt) método para classificar um linfoma difuso de grande célula b (dlbcl), uma ou mais mídias de armazenamento legíveis por computador, sistema de computação adaptado e kit
MX2016013255A (es) Metodos y composiciones para detectar proteinas mal plegadas.
WO2016130572A3 (en) Methods of determining levels of exposure to radiation and uses thereof
AU2015308620A8 (en) Early lung cancer detection by DNA methylation phenotyping of sputum-derived cells
EP3495502A3 (en) Biomarkers for premature birth
MX2017013390A (es) Método para el tratamiento de cáncer pulmonar.
BR112016029562A2 (pt) métodos para tratar, diagnosticar e prognosticar uma malignidade hematológica
WO2018097614A3 (ko) 유방암 환자의 화학치료 유용성 예측 방법
PH12014502410A1 (en) Breast cancer prognosis, prediction of progesterone receptor subtype and|prediction of response to antiprogestin treatment based on gene expression
WO2019074615A3 (en) In vitro methods for skin therapeutic compound discovery using skin age biomarkers
BR112017006315A2 (pt) agente terapêutico, uso de um agente terapêutico, métodos in vitro para determinar se um sujeito com melanoma tem um risco maior de desenvolver metástase, de determinação de um regime de tratamento para um sujeito que sofre de melanoma, de tratamento de um sujeito que sofre de melanoma, ensaio in vitro para predizer o risco aumentado de metástase e kits
BR112015012548A2 (pt) método
MY195697A (en) Method of Prognosing and Predicting Breast Cancer Recurrence, Markers Employed Therein and Kit Thereof

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]